---
title: "Vera Bradley posts Q1 fiscal 2027 revenue up 7.8% to $55.7M; non-GAAP loss narrows to $(0.09) per share"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289462310.md"
description: "Vera Bradley reported Q1 fiscal 2027 net revenues of $55.7 million, a 7.8% increase year-over-year, marking its first revenue growth since FY22. Non-GAAP net loss narrowed to $(0.09) per share. The company highlighted gross margin expansion to 51.8%, significant inventory reduction, and improved operating performance driven by the 'Project Sunshine' transformation, strategic collaborations, and channel optimizations."
datetime: "2026-06-11T12:03:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289462310.md)
  - [en](https://longbridge.com/en/news/289462310.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289462310.md)
generator: "portal-rs"
---

# Vera Bradley posts Q1 fiscal 2027 revenue up 7.8% to $55.7M; non-GAAP loss narrows to $(0.09) per share

Vera Bradley reported first quarter fiscal 2027 consolidated net revenues of $55.7 million, a 7.8% increase versus the prior-year quarter, and its first quarter of revenue growth since fiscal 2022. GAAP net loss from continuing operations was $(4.8) million, or $(0.17) per diluted share; on a non-GAAP basis the net loss narrowed to $(2.5) million, or $(0.09) per diluted share. The company highlighted gross margin expansion, reduced inventory and a substantial reduction in operating loss driven by cost optimization and channel improvements.

**Financial Highlights**

-   Net revenues: $55.7 million for the thirteen weeks ended May 2, 2026 (up from $51.7 million prior year).
-   Gross profit: $28.8 million, representing a 51.8% gross margin (prior year gross profit $22.8 million, 44.1%).
-   Operating loss from continuing operations (GAAP): $(4.6) million for the quarter (prior year $(17.9) million).
-   Net loss from continuing operations (GAAP): $(4.8) million, or $(0.17) per diluted share; Non-GAAP net loss: $(2.5) million, or $(0.09) per diluted share.
-   Cash and cash equivalents: $12.5 million at May 2, 2026; quarter-end inventory: $73.0 million (26% reduction year-over-year).

**Business Highlights**

-   Project Sunshine transformation delivered the company's first quarter of overall revenue growth since Q4 FY22 and drove improved customer engagement across channels.
-   Direct segment revenues were $44.9 million (up 4.1% year-over-year) with comparable sales increasing 13.4%, supported by better ecommerce conversion, higher average ticket, and increased traffic in outlet and full-line stores; three underperforming full-line stores were closed during the quarter.
-   Indirect segment revenues rose 26.6% to $10.8 million, driven by improvements in specialty and department store partnerships and cut-to-order sales growth across key accounts.
-   Inventory management improved materially through tighter assortment planning and buy management, producing the leanest first-quarter inventory position since fiscal 2011 and a $5.3 million Project Restoration inventory reserve.
-   Strategic collaborations with Bath & Body Works and Target drove strong engagement and new-customer acquisition, with approximately 80% of customers engaging through these partnerships being new to the brand.

Original SEC Filing: Vera Bradley, Inc. \[ VRA \] - 8-K - Jun. 11, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [VRA.US](https://longbridge.com/en/quote/VRA.US.md)
- [BBWI.US](https://longbridge.com/en/quote/BBWI.US.md)
- [TGT.US](https://longbridge.com/en/quote/TGT.US.md)

## Related News & Research

- [Cel-Sci GAAP EPS of -$0.47](https://longbridge.com/en/news/296114461.md)
- [Aptorum Group GAAP EPS of -$1.60](https://longbridge.com/en/news/296654186.md)
- [XORTX Therapeutics Inc. GAAP EPS of -$1.05](https://longbridge.com/en/news/296650983.md)
- [Enveric Biosciences GAAP EPS of -$0.76](https://longbridge.com/en/news/296075035.md)
- [Lufax Holding GAAP EPADS of -$0.04](https://longbridge.com/en/news/296274582.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**